FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 154 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... April 5, 2023 Why consistent and funded cancer policies are key to improving cancer... November 1, 2022 EMA Recommends Additional Extensions of Indications for Pembrolizumab October 7, 2024 Bra Straps with Disappearing Message Remind Women to Check Their Breasts... April 12, 2021 Load more HOT NEWS First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with... Prize winning early detection research EMA Recommends Granting a Marketing Authorisation for Azacitidine 9-Year-Old Has His Final Cancer Treatment After 3 Years – Breaks...
